- Home
- ATOS vs HNNA Comparison
ATOS vs HNNA Comparison
Compare ATOS & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- HNNA
- Stock Information
- Founded
- ATOS 2009
- HNNA 1989
- Country
- ATOS United States
- HNNA United States
- Employees
- ATOS N/A
- HNNA N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- HNNA Investment Managers
- Sector
- ATOS Health Care
- HNNA Finance
- Exchange
- ATOS Nasdaq
- HNNA Nasdaq
- Market Cap
- ATOS 107.2M
- HNNA 98.7M
- IPO Year
- ATOS 2012
- HNNA N/A
- Fundamental
- Price
- ATOS $0.78
- HNNA $11.18
- Analyst Decision
- ATOS Strong Buy
- HNNA
- Analyst Count
- ATOS 3
- HNNA 0
- Target Price
- ATOS $6.17
- HNNA N/A
- AVG Volume (30 Days)
- ATOS 1.3M
- HNNA 11.6K
- Earning Date
- ATOS 08-12-2025
- HNNA 08-06-2025
- Dividend Yield
- ATOS N/A
- HNNA 5.05%
- EPS Growth
- ATOS N/A
- HNNA 56.56
- EPS
- ATOS N/A
- HNNA 1.25
- Revenue
- ATOS N/A
- HNNA $35,816,000.00
- Revenue This Year
- ATOS N/A
- HNNA N/A
- Revenue Next Year
- ATOS N/A
- HNNA N/A
- P/E Ratio
- ATOS N/A
- HNNA $8.82
- Revenue Growth
- ATOS N/A
- HNNA 32.04
- 52 Week Low
- ATOS $0.55
- HNNA $8.43
- 52 Week High
- ATOS $1.66
- HNNA $13.88
- Technical
- Relative Strength Index (RSI)
- ATOS 45.59
- HNNA 42.52
- Support Level
- ATOS $0.81
- HNNA $10.49
- Resistance Level
- ATOS $0.80
- HNNA $11.31
- Average True Range (ATR)
- ATOS 0.03
- HNNA 0.64
- MACD
- ATOS -0.00
- HNNA -0.04
- Stochastic Oscillator
- ATOS 39.58
- HNNA 31.15
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About HNNA Hennessy Advisors Inc.
Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.